Actively Recruiting
Led by University Hospital, Akershus · Updated on 2025-08-12
380
Participants Needed
12
Research Sites
130 weeks
Total Duration
U
University Hospital, Akershus
Lead Sponsor
U
University of Oslo
Collaborating Sponsor
Researchers are evaluating the safety and effectiveness of stopping antibiotic treatment early in adults hospitalized with respiratory viral infections. This study focuses on patients with moderately severe disease who test positive for respiratory viruses such as influenza, respiratory syncytial virus, parainfluenza virus, or human metapneumovirus. The goal is to determine if early discontinuation of antibiotics leads to similar clinical outcomes compared to continuing antibiotic therapy, aiming to reduce unnecessary antibiotic use and combat antimicrobial resistance. Participants are randomly assigned to either stop antibiotic therapy as started by their admitting physician or to continue antibiotic therapy without changes. The study monitors early clinical response at 120 hours after randomization, defined by survival with symptom improvement and no need for rescue antibiotics. Secondary assessments include mortality rates, hospital stay duration, antibiotic use, and readmission rates, all measured during hospital admission and up to 30 days after discharge. During the trial, participants undergo nasopharyngeal swab testing to confirm viral infection and are monitored closely for symptoms, survival, and antibiotic use. Researchers evaluate clinical response at 120 hours and track outcomes such as mortality, hospital stay length, and antibiotic doses until discharge and 30 days later. The study aims to gather detailed safety and efficacy data over the hospital stay and follow-up period, supporting more targeted antibiotic use in viral respiratory infections.
CONDITIONS
Antibiotic Therapy in Viral Airway Infections
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 120 hours after randomization
Participants are randomized to either stop antibiotic therapy or continue antibiotic therapy as prescribed by their physician to assess early clinical response.
1 baseline visit and follow-up visits during hospital admission (commonly 3-5 days)
Duration - 30 days after hospital discharge
Participants are monitored for outcomes including 30-day mortality, new antibiotic therapy, and readmission after hospital discharge.
1 to 2 visits depending on follow-up assessments
Total: 12 locations
1
Haukeland University Hospital
Bergen, Norway, 5021
Not Yet Recruiting
2
Drammen Hospital, Vestre Viken Hospital Trust
Drammen, Norway, 3004
Actively Recruiting
3
Bærum Hospital, Vestre Viken Hospital Trust
Gjettum, Norway, 1346
Not Yet Recruiting
4
Sykehuset Østfold HF
Grålum, Norway, 1714
Actively Recruiting
5
Sørlandet sykehus HF
Kristiansand, Norway
Actively Recruiting
6
Akershus University Hospital
Lørenskog, Norway, 1478
Actively Recruiting
7
Oslo University Hospital, Ullevål
Oslo, Norway, 0424
Actively Recruiting
8
Telemark Hospital Trust
Skien, Norway, 3710
Not Yet Recruiting
9
Stavanger University Hospital
Stavanger, Norway, 4068
Actively Recruiting
10
University Hospital of North Norway
Tromsø, Norway, 9038
Actively Recruiting
11
St. Olavs hospital
Trondheim, Norway, 7006
Not Yet Recruiting
12
Sykehuset i Vestfold HF
Tønsberg, Norway, 3103
Actively Recruiting
M
Magnus N Lyngbakken, MD PhD
O
Olav Dalgard, MD PhD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Magrit Jarlsdatter Hovind, Jan Erik Berdal, Jūratė Šaltytė Benth...
https://pubmed.ncbi.nlm.nih.gov/42015169